Treatment Outcome in Non-Metastatic Gastric Cancer “A Retrospective Study “ | ||
| Al-Azhar International Medical Journal | ||
| Volume 2023, Issue 1, January 2023 | ||
| DOI: 10.58675/2682-339X.1705 | ||
| Authors | ||
| Alaa Mahfouz Mahmoud Abd Elaziz1; Ahmed Yousry Elagmawi2; Sherif Mohamed Azzam3 | ||
| 1Resident doctor at clinical oncology and nuclear medicine, faculty of medicine , al azhar university Cairo , Egypt. | ||
| 2clinical oncology and nuclear medicine , faculty of medicine , al azhar university Cairo , Egypt. | ||
| 3clinical oncology and nuclear medicine , faculty of medicine , al azhar university Cairo , Egypt. | ||
| Abstract | ||
| Background: The best surgical therapy technique for elderly patients with stomach cancer must be carefully studied because of their high vulnerability. Aim and objectives: This study's main objective was to assess our treatment modalities in non-metastatic gastric cancer in terms of disease-free survival, overall survival, and related toxicity. The secondary objective has been to display the clinico-epidemiologic profile of this disease. Subjects and methods: This retrospective study was conducted in Clinical Oncology and Nuclear Medicine Department at Al-Hussein university Hospital between Jan 2016 and Jun.2021. This study was conducted on 40 patients presented by a pathologically confirmed diagnosis with non-metastatic gastric adenocarcinoma. Results: Surgery + CCRT (better prognosis with hazard ratio=0.007, surgery (hazard ratio = 0.021) are statistically significant predictors of overall survival among studied cases; Bad prognosis is detected for cases with partial response (HR=32) and progressive disease (HR=17), inadequate LN have bad prognosis (HR=13.17). Conclusion: The current study showed that adjuvant concurrent chemoradiotherapy was safe, effective, and practical as a therapy for non-metastatic gastric cancer, and resulted in higher disease-free survival compared to perioperative chemotherapy. | ||
|
Statistics Article View: 25 |
||
